Feasibility of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia

References

• Gorin N. Autologous stem cell transplantation for adult acute leukemia. Curr Opin Oncol 2002; 14: 152–159
   PubMed Web of Science ®Google Scholar
• Linker C A. Autologous stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplant 2003; 31: 731–738
   PubMed Web of Science ®Google Scholar
• Mathews V, DiPersio J F. Stem cell transplantation in acute myelogenous leukemia in first remission: what are the options?. Curr Hematol Rep 2004; 3: 235–241
   PubMedGoogle Scholar
• Breems D A, Lowenberg B. Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia. Br J Haematol 2005; 128: 59–65
   PubMed Web of Science ®Google Scholar
• Zittoun R A, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217–223
   PubMed Web of Science ®Google Scholar
• Cassileth P A, Harrington D P, Appelbaum F R, Lazarus H M, Rowe J M, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1656
   PubMed Web of Science ®Google Scholar
• Burnett A K, Goldstone A H, Stevens R M, Hann I M, Rees J K, Gray R G, Wheatley K. Randomized comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia first remission: results of MRC AML 10 trial. Lancet 1998; 351: 700–708
   PubMed Web of Science ®Google Scholar
• Nathan P C, Sung L, Crump M, Beyene J. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst 2004; 96: 38–45
   PubMed Web of Science ®Google Scholar
• SEER Cancer Statistics Review, 1973 – 1998, L AG Ries, M P Eisner, C L Kosary. National Cancer Institute, Bethesda, MD 2001
   Google Scholar
• Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun M J. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26
   PubMed Web of Science ®Google Scholar
• Ferrara F, Mirto S, Zagonel V, Pinto A. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. Leuk Lymphoma 1998; 29: 375–382
   PubMed Web of Science ®Google Scholar
• Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004; 5: 443–450
   PubMed Web of Science ®Google Scholar
• Pinto A, Zagonel V, Ferrara F. Acute myeloid leukaemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol/Hematol 2001; 39: 275–287
   PubMed Web of Science ®Google Scholar
• Ferrara F, Palmieri S, Mele G. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukaemia. Haematologica 2004; 89: 998–1008
   PubMed Web of Science ®Google Scholar
• Sekeres M A, Stone R M. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 2002; 14: 24–30
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Jehn U, Thomas X, De Cataldo F, Fillet G, Belhabri A, et al. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia 1999; 13: 843–849
   PubMed Web of Science ®Google Scholar
• Montillo M, Tedeschi A, Pagano L, Venditti A, Ferrara F, Fabris P, et al. Feasibility of peripheral blood stem cell rescue as intensification in elderly patients with acute myelocytic leukaemia: a pilot study from the GIMEMA group. Br J Haematol 2000; 111: 334–337
   PubMed Web of Science ®Google Scholar
• Oriol A, Ribera J M, Esteve J, Guardia R, Brunet S, Bueno J, et al. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol. Haematologica 2004; 89: 791–800
   PubMed Web of Science ®Google Scholar
• Olivieri A, Capelli D, Montanari M, Brunori M, Massidda D, Poloni A, et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. Bone Marrow Transplant 2001; 27: 1189–1195
   PubMed Web of Science ®Google Scholar
• Gorin N C, Labopin M, Pichard P, Sierra J, Fiere D, Rio B, et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. Br J Haematol 2000; 110: 887–893
   PubMed Web of Science ®Google Scholar
• Ferrara F, Venditti A, Carella A M, Jr, Cantore N, Buccisano F, Tamburini A, et al. Autologous stem cell transplantation for patients with acute myeloid leukaemia aged over 60 years. Eur J Haematol 2002; 69: 200–204
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Kopecky K J, Büchner T, Willman C L, Estey E H, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukaemia. J Clin Oncol 2003; 21: 4642–4649
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-transretinoic acid and chemotherapy. J Clin Oncol 2000; 18: 1295–1300
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C J, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukaemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO handbook for reporting results of cancer treatment. World Health Organization, Geneva 1979; 38
   Google Scholar
• Ferrara F, D'Arco A M, De Simone M, Mele G, Califano C, Pocali B, et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukaemia. Haematologica/Hematol J 2005; 90: 776–784
   PubMed Web of Science ®Google Scholar
• Ferrara F, Palmieri S, Annunziata M, Viola A, Pocali B, Califano C, et al. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukaemia aged over 60 years undergoing autologous stem cell transplantation. Bone Marrow Transplant 2004; 34: 573–576
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Sekeres M A, Stone R M, Zahrieh D, Neuberg D, Morrison V, De Angelo D J, et al. Decision-making and quality of life in older adults with acute myeloid leukaemia or advanced myelodysplastic syndrome. Leukemia 2004; 18: 809–816
   PubMed Web of Science ®Google Scholar
• Ferrara F, Annunziata M, Copia C, Magrin S, Mele G, Mirto S. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia. Haematologica 1998; 83: 126–131
   PubMed Web of Science ®Google Scholar
• Vey N, Coso D, Bardou V J, Stoppa A M, Braud A C, Bouabdallah R, et al. The benefit of induction chemotherapy in patients age ≥75 years. Cancer 2004; 101: 325–331
   PubMed Web of Science ®Google Scholar
• Tallman M S, Gilliland G, Rowe J M. Drug therapy for acute myeloid leukemia. Blood 2005; 15: 1154–1163
   Web of Science ®Google Scholar
• Rowe J M. Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?. Leukemia 2005; 19: 1324–1327
   PubMed Web of Science ®Google Scholar
• Mengis C, Aebi S, Tobler A, Dahler W, Fey M F. Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 2003; 21: 3933–3939
   PubMed Web of Science ®Google Scholar
• Gross C P, Herrin J E, Won N G, Krumholz H M. Enrolling older persons in cancer trials: the effect of sociodemographic, protocol, and recruitment center characteristics. J Clin Oncol 2005; 23: 4755–4763
   PubMed Web of Science ®Google Scholar
• Visani G, Lemoli R M, Tosi P, Martinelli G, Testoni N, Ricci P, et al. Fludarabine containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105: 775–779
   PubMed Web of Science ®Google Scholar
• Robak T. Purine nucleoside analogues in the treatment of myeloid leukemias. Leuk Lymphoma 2003; 44: 391–409
   PubMed Web of Science ®Google Scholar
• Tournilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363–365
   PubMed Web of Science ®Google Scholar
• Ferrara F, Palmieri S, Pocali B, Pollio F, Viola A, Annunziata S, et al. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). Eur J Haematol 2002; 68: 203–209
   PubMed Web of Science ®Google Scholar